Cardiovascular Pharmacology
Dizziness and syncope (transient loss of consciousness) result from diverse pathophysiologic mechanisms affecting cerebral perfusion, vestibular function, cardiovascular stability, or metabolic homeostasis. Accurate etiologic diagnosis is paramount, as pharmacological management must target the underlying disorder rather than symptomatic treatment alone. Therapeutic approaches span vestibular suppressants, cardiovascular agents, neuropsychiatric medications, and metabolic corrections, each addressing specific pathophysiologic derangements while minimizing adverse effects and drug interactions.
📋 Abbreviations Used in This Article
- BPPV: Benign Paroxysmal Positional Vertigo
- GABA: Gamma-Aminobutyric Acid
- SSRIs: Selective Serotonin Reuptake Inhibitors
- ECG: Electrocardiogram
- IV: Intravenous
🔬 Etiologic Classification
Dizziness and syncope arise from multiple pathophysiologic mechanisms:
Major Etiologic Categories
- Vestibular Disorders: Ménière's disease, vestibular neuritis, benign paroxysmal positional vertigo, labyrinthitis
- Cardiovascular Causes: Orthostatic hypotension, cardiac arrhythmias (bradycardia, tachycardia), valvular heart disease
- Neurologic Disorders: Vertebrobasilar insufficiency, migraine-associated vertigo, multiple sclerosis
- Metabolic Derangements: Anemia, hypoglycemia, electrolyte imbalances, dehydration
- Psychiatric Conditions: Anxiety disorders, panic attacks, hyperventilation syndrome
- Drug-Induced: Antihypertensives, sedatives, anticholinergics, aminoglycosides
🎯 Diagnostic Priority: Treatment efficacy depends on accurate identification of underlying etiology. Empiric symptomatic therapy without etiologic diagnosis risks therapeutic failure and potential harm. Comprehensive evaluation including history, physical examination, orthostatic vital signs, and targeted investigations guides appropriate pharmacological intervention.
💊 Vestibular Suppressants
These agents reduce vertigo, nausea, and vomiting associated with vestibular dysfunction:
Antihistamines
- Meclizine: 25 to 50 mg orally as needed; first-generation H1 antagonist
- Dimenhydrinate: 50 mg every 4 to 6 hours; combined antihistamine and anticholinergic
- Promethazine: Phenothiazine with antihistaminic properties for severe nausea
- Mechanism: Block histamine receptors in vestibular nuclei and vomiting center
- Adverse Effects: Sedation, dry mouth, blurred vision, urinary retention
Anticholinergics
- Scopolamine: Transdermal patch (1.5 mg over 72 hours)
- Mechanism: Blocks muscarinic receptors in vestibular pathways
- Indications: Motion sickness prophylaxis, acute vertigo
- Contraindications: Narrow-angle glaucoma, urinary retention, elderly (delirium risk)
- Adverse Effects: Dry mouth, blurred vision, confusion, memory impairment
Benzodiazepines
- Diazepam: 2 to 5 mg orally two to three times daily
- Lorazepam: 0.5 to 1 mg orally as needed
- Mechanism: Enhance GABA-A receptor activity, suppress vestibular responses
- Indications: Severe acute vertigo, anxiety-related dizziness
- Limitations: Short-term use only; risk of dependence, sedation, cognitive impairment
Clinical Considerations
- Reserve vestibular suppressants for acute symptomatic relief
- Prolonged use may delay central compensation
- Avoid in elderly due to fall risk and cognitive effects
- Combine with vestibular rehabilitation for optimal outcomes
⚠️ Important Caveat: Vestibular suppressants provide symptomatic relief but do not address underlying pathology. Chronic use may impair central vestibular compensation, potentially prolonging recovery. These agents are most appropriate for acute symptomatic management while definitive treatment targets the primary disorder.
🔄 Agents for Ménière's Disease
Ménière's disease management focuses on reducing endolymphatic hydrops:
Diuretics
- Hydrochlorothiazide: 25 mg daily or 50 mg daily
- Acetazolamide: 250 mg twice daily; carbonic anhydrase inhibitor
- Mechanism: Reduce endolymphatic fluid accumulation
- Adjunctive Measures: Low-sodium diet (less than 2 grams daily)
- Monitoring: Electrolytes, renal function
Additional Therapies
- Betahistine: 16 mg three times daily (not FDA-approved in US); histamine analogue
- Mechanism: Increases cochlear blood flow, reduces endolymphatic pressure
- Intratympanic Corticosteroids: For refractory cases
- Gentamicin Ablation: Chemical labyrinthectomy for intractable vertigo
🩸 Management of Orthostatic Hypotension
Pharmacological intervention increases blood pressure to prevent syncope from postural hypotension:
| Agent | Mechanism | Dosing | Adverse Effects |
|---|---|---|---|
| Midodrine | Alpha-1 adrenergic agonist; peripheral vasoconstriction | 2.5 to 10 mg three times daily (avoid evening dose) | Supine hypertension, piloerection, urinary retention |
| Fludrocortisone | Mineralocorticoid; increases sodium and water retention | 0.1 to 0.2 mg daily | Hypertension, hypokalemia, edema, heart failure exacerbation |
| Droxidopa | Norepinephrine precursor; increases sympathetic tone | 100 to 600 mg three times daily | Headache, dizziness, nausea |
📊 Non-Pharmacological Measures: Physical countermaneuvers, adequate hydration (2 to 3 liters daily), increased salt intake (unless contraindicated), compression stockings, head-of-bed elevation, and gradual position changes complement pharmacotherapy for orthostatic hypotension management.
❤️ Cardiac Arrhythmia Management
Syncope from cardiac arrhythmias requires rhythm control or rate control strategies:
Bradyarrhythmias
- Atropine: Acute management (0.5 to 1 mg IV)
- Permanent Pacemaker: Definitive treatment for symptomatic bradycardia
- Medication Review: Discontinue or adjust beta-blockers, calcium channel blockers, digoxin
Tachyarrhythmias
- Beta-Blockers: Metoprolol, atenolol for rate control
- Amiodarone: Rhythm control for recurrent ventricular arrhythmias
- Flecainide, Propafenone: Supraventricular tachycardia management
- ICD Placement: For life-threatening ventricular arrhythmias
🎯 ECG-Guided Therapy: Arrhythmia management requires electrocardiographic documentation of rhythm disturbance. Empiric antiarrhythmic therapy without documented arrhythmia risks proarrhythmic complications. Holter monitoring or event recorders facilitate rhythm-symptom correlation.
🧠 Psychiatric Disorder Management
Anxiety-associated dizziness responds to anxiolytic and antidepressant therapies:
Long-Term Management
- SSRIs: Sertraline (50 to 200 mg daily), escitalopram (10 to 20 mg daily)
- SNRIs: Venlafaxine for comorbid depression and anxiety
- Mechanism: Modulate serotonergic neurotransmission
- Onset: 2 to 4 weeks for therapeutic effect
Acute Episodes
- Benzodiazepines: Lorazepam, alprazolam for acute panic attacks
- Limitation: Short-term use only due to dependence risk
- Cognitive Behavioral Therapy: Essential adjunct to pharmacotherapy
🩺 Metabolic Disorder Correction
Address underlying metabolic derangements causing dizziness or syncope:
| Condition | Pharmacological Intervention | Monitoring |
|---|---|---|
| Iron Deficiency Anemia | Ferrous sulfate 325 mg (65 mg elemental iron) two to three times daily | Hemoglobin, ferritin at 4 to 6 weeks |
| Pernicious Anemia | Cyanocobalamin 1000 mcg intramuscularly weekly, then monthly | Complete blood count, vitamin B12 levels |
| Acute Hypoglycemia | Oral glucose 15 to 20 grams or IV dextrose 50% (25 grams) | Fingerstick glucose every 15 minutes |
| Severe Hypoglycemia | Glucagon 1 mg intramuscularly or subcutaneously | Blood glucose, assess for rebound hypoglycemia |
🛡️ Preventive and Supportive Measures
Non-pharmacological interventions are essential adjuncts:
General Preventive Strategies
- Postural Changes: Gradual position transitions, avoid sudden standing
- Hydration: Maintain adequate fluid intake (2 to 3 liters daily)
- Dietary Measures: Regular meals prevent hypoglycemia
- Alcohol and Caffeine: Limit intake to reduce dehydration and arrhythmia risk
- Medication Review: Identify and adjust causative medications
- Fall Prevention: Environmental modifications, assistive devices
📊 Summary of Pharmacotherapy
| Drug Class | Mechanism of Action | Primary Indications | Key Considerations |
|---|---|---|---|
| Antihistamines | H1 receptor antagonism in vestibular nuclei | Vertigo, motion sickness | Sedation, anticholinergic effects |
| Anticholinergics | Muscarinic receptor blockade | Motion sickness, acute vertigo | Contraindicated in glaucoma, elderly |
| Benzodiazepines | GABA-A receptor enhancement | Severe vertigo, anxiety-related dizziness | Short-term use, dependence risk |
| Diuretics | Reduce endolymphatic fluid | Ménière's disease | Electrolyte monitoring required |
| Vasopressors | Increase blood pressure | Orthostatic hypotension | Monitor supine hypertension |
| Antiarrhythmics | Rate or rhythm control | Cardiac arrhythmias | ECG-guided therapy essential |
| SSRIs | Serotonin reuptake inhibition | Anxiety-related dizziness | Delayed onset (2 to 4 weeks) |
🎯 Clinical Pearls
Essential considerations for managing dizziness and syncope:
- Accurate etiologic diagnosis is paramount before initiating pharmacotherapy
- Vestibular suppressants provide symptomatic relief but should be time-limited
- Orthostatic hypotension requires both pharmacological and non-pharmacological measures
- Cardiac syncope necessitates ECG documentation before antiarrhythmic therapy
- Avoid vestibular suppressants in elderly due to fall risk and cognitive impairment
- Medication review is essential as polypharmacy commonly causes dizziness
- Anxiety-related dizziness responds to SSRIs, not chronic benzodiazepines
- Address metabolic causes (anemia, hypoglycemia) through specific replacement therapy
🔬 Pharmacology Study Tips:
- Understand mechanisms: Vestibular suppression, cardiovascular effects, metabolic corrections
- Know contraindications: Anticholinergics in glaucoma, benzodiazepines in elderly
- Remember monitoring requirements: Electrolytes (diuretics), supine BP (midodrine), ECG (antiarrhythmics)
- Recognize drug-induced dizziness: Antihypertensives, sedatives, anticholinergics
💊 Vestibular Suppressants
These agents reduce vertigo, nausea, and vomiting associated with vestibular dysfunction:
Antihistamines
- Meclizine: 25 to 50 mg orally as needed; first-generation H1 antagonist
- Dimenhydrinate: 50 mg every 4 to 6 hours; combined antihistamine and anticholinergic
- Promethazine: Phenothiazine with antihistaminic properties for severe nausea
- Mechanism: Block histamine receptors in vestibular nuclei and vomiting center
- Adverse Effects: Sedation, dry mouth, blurred vision, urinary retention
Anticholinergics
- Scopolamine: Transdermal patch (1.5 mg over 72 hours)
- Mechanism: Blocks muscarinic receptors in vestibular pathways
- Indications: Motion sickness prophylaxis, acute vertigo
- Contraindications: Narrow-angle glaucoma, urinary retention, elderly (delirium risk)
- Adverse Effects: Dry mouth, blurred vision, confusion, memory impairment
Benzodiazepines
- Diazepam: 2 to 5 mg orally two to three times daily
- Lorazepam: 0.5 to 1 mg orally as needed
- Mechanism: Enhance GABA-A receptor activity, suppress vestibular responses
- Indications: Severe acute vertigo, anxiety-related dizziness
- Limitations: Short-term use only; risk of dependence, sedation, cognitive impairment
Clinical Considerations
- Reserve vestibular suppressants for acute symptomatic relief
- Prolonged use may delay central compensation
- Avoid in elderly due to fall risk and cognitive effects
- Combine with vestibular rehabilitation for optimal outcomes
⚠️ Important Caveat: Vestibular suppressants provide symptomatic relief but do not address underlying pathology. Chronic use may impair central vestibular compensation, potentially prolonging recovery. These agents are most appropriate for acute symptomatic management while definitive treatment targets the primary disorder.
🔄 Agents for Ménière's Disease
Ménière's disease management focuses on reducing endolymphatic hydrops:
Diuretics
- Hydrochlorothiazide: 25 mg daily or 50 mg daily
- Acetazolamide: 250 mg twice daily; carbonic anhydrase inhibitor
- Mechanism: Reduce endolymphatic fluid accumulation
- Adjunctive Measures: Low-sodium diet (less than 2 grams daily)
- Monitoring: Electrolytes, renal function
Additional Therapies
- Betahistine: 16 mg three times daily (not FDA-approved in US); histamine analogue
- Mechanism: Increases cochlear blood flow, reduces endolymphatic pressure
- Intratympanic Corticosteroids: For refractory cases
- Gentamicin Ablation: Chemical labyrinthectomy for intractable vertigo
🩸 Management of Orthostatic Hypotension
Pharmacological intervention increases blood pressure to prevent syncope from postural hypotension:
| Agent | Mechanism | Dosing | Adverse Effects |
|---|---|---|---|
| Midodrine | Alpha-1 adrenergic agonist; peripheral vasoconstriction | 2.5 to 10 mg three times daily (avoid evening dose) | Supine hypertension, piloerection, urinary retention |
| Fludrocortisone | Mineralocorticoid; increases sodium and water retention | 0.1 to 0.2 mg daily | Hypertension, hypokalemia, edema, heart failure exacerbation |
| Droxidopa | Norepinephrine precursor; increases sympathetic tone | 100 to 600 mg three times daily | Headache, dizziness, nausea |
📊 Non-Pharmacological Measures: Physical countermaneuvers, adequate hydration (2 to 3 liters daily), increased salt intake (unless contraindicated), compression stockings, head-of-bed elevation, and gradual position changes complement pharmacotherapy for orthostatic hypotension management.
❤️ Cardiac Arrhythmia Management
Syncope from cardiac arrhythmias requires rhythm control or rate control strategies:
Bradyarrhythmias
- Atropine: Acute management (0.5 to 1 mg IV)
- Permanent Pacemaker: Definitive treatment for symptomatic bradycardia
- Medication Review: Discontinue or adjust beta-blockers, calcium channel blockers, digoxin
Tachyarrhythmias
- Beta-Blockers: Metoprolol, atenolol for rate control
- Amiodarone: Rhythm control for recurrent ventricular arrhythmias
- Flecainide, Propafenone: Supraventricular tachycardia management
- ICD Placement: For life-threatening ventricular arrhythmias
🎯 ECG-Guided Therapy: Arrhythmia management requires electrocardiographic documentation of rhythm disturbance. Empiric antiarrhythmic therapy without documented arrhythmia risks proarrhythmic complications. Holter monitoring or event recorders facilitate rhythm-symptom correlation.
🧠 Psychiatric Disorder Management
Anxiety-associated dizziness responds to anxiolytic and antidepressant therapies:
Long-Term Management
- SSRIs: Sertraline (50 to 200 mg daily), escitalopram (10 to 20 mg daily)
- SNRIs: Venlafaxine for comorbid depression and anxiety
- Mechanism: Modulate serotonergic neurotransmission
- Onset: 2 to 4 weeks for therapeutic effect
Acute Episodes
- Benzodiazepines: Lorazepam, alprazolam for acute panic attacks
- Limitation: Short-term use only due to dependence risk
- Cognitive Behavioral Therapy: Essential adjunct to pharmacotherapy
🩺 Metabolic Disorder Correction
Address underlying metabolic derangements causing dizziness or syncope:
| Condition | Pharmacological Intervention | Monitoring |
|---|---|---|
| Iron Deficiency Anemia | Ferrous sulfate 325 mg (65 mg elemental iron) two to three times daily | Hemoglobin, ferritin at 4 to 6 weeks |
| Pernicious Anemia | Cyanocobalamin 1000 mcg intramuscularly weekly, then monthly | Complete blood count, vitamin B12 levels |
| Acute Hypoglycemia | Oral glucose 15 to 20 grams or IV dextrose 50% (25 grams) | Fingerstick glucose every 15 minutes |
| Severe Hypoglycemia | Glucagon 1 mg intramuscularly or subcutaneously | Blood glucose, assess for rebound hypoglycemia |
🛡️ Preventive and Supportive Measures
Non-pharmacological interventions are essential adjuncts:
General Preventive Strategies
- Postural Changes: Gradual position transitions, avoid sudden standing
- Hydration: Maintain adequate fluid intake (2 to 3 liters daily)
- Dietary Measures: Regular meals prevent hypoglycemia
- Alcohol and Caffeine: Limit intake to reduce dehydration and arrhythmia risk
- Medication Review: Identify and adjust causative medications
- Fall Prevention: Environmental modifications, assistive devices
📊 Summary of Pharmacotherapy
| Drug Class | Mechanism of Action | Primary Indications | Key Considerations |
|---|---|---|---|
| Antihistamines | H1 receptor antagonism in vestibular nuclei | Vertigo, motion sickness | Sedation, anticholinergic effects |
| Anticholinergics | Muscarinic receptor blockade | Motion sickness, acute vertigo | Contraindicated in glaucoma, elderly |
| Benzodiazepines | GABA-A receptor enhancement | Severe vertigo, anxiety-related dizziness | Short-term use, dependence risk |
| Diuretics | Reduce endolymphatic fluid | Ménière's disease | Electrolyte monitoring required |
| Vasopressors | Increase blood pressure | Orthostatic hypotension | Monitor supine hypertension |
| Antiarrhythmics | Rate or rhythm control | Cardiac arrhythmias | ECG-guided therapy essential |
| SSRIs | Serotonin reuptake inhibition | Anxiety-related dizziness | Delayed onset (2 to 4 weeks) |
🎯 Clinical Pearls
Essential considerations for managing dizziness and syncope:
- Accurate etiologic diagnosis is paramount before initiating pharmacotherapy
- Vestibular suppressants provide symptomatic relief but should be time-limited
- Orthostatic hypotension requires both pharmacological and non-pharmacological measures
- Cardiac syncope necessitates ECG documentation before antiarrhythmic therapy
- Avoid vestibular suppressants in elderly due to fall risk and cognitive impairment
- Medication review is essential as polypharmacy commonly causes dizziness
- Anxiety-related dizziness responds to SSRIs, not chronic benzodiazepines
- Address metabolic causes (anemia, hypoglycemia) through specific replacement therapy
🔬 Pharmacology Study Tips:
- Understand mechanisms: Vestibular suppression, cardiovascular effects, metabolic corrections
- Know contraindications: Anticholinergics in glaucoma, benzodiazepines in elderly
- Remember monitoring requirements: Electrolytes (diuretics), supine BP (midodrine), ECG (antiarrhythmics)
- Recognize drug-induced dizziness: Antihypertensives, sedatives, anticholinergics
📊 Summary of Pharmacotherapy
| Drug Class | Mechanism of Action | Primary Indications | Key Considerations |
|---|---|---|---|
| Antihistamines | H1 receptor antagonism in vestibular nuclei | Vertigo, motion sickness | Sedation, anticholinergic effects |
| Anticholinergics | Muscarinic receptor blockade | Motion sickness, acute vertigo | Contraindicated in glaucoma, elderly |
| Benzodiazepines | GABA-A receptor enhancement | Severe vertigo, anxiety-related dizziness | Short-term use, dependence risk |
| Diuretics | Reduce endolymphatic fluid | Ménière's disease | Electrolyte monitoring required |
| Vasopressors | Increase blood pressure | Orthostatic hypotension | Monitor supine hypertension |
| Antiarrhythmics | Rate or rhythm control | Cardiac arrhythmias | ECG-guided therapy essential |
| SSRIs | Serotonin reuptake inhibition | Anxiety-related dizziness | Delayed onset (2 to 4 weeks) |
🎯 Clinical Pearls
Essential considerations for managing dizziness and syncope:
- Accurate etiologic diagnosis is paramount before initiating pharmacotherapy
- Vestibular suppressants provide symptomatic relief but should be time-limited
- Orthostatic hypotension requires both pharmacological and non-pharmacological measures
- Cardiac syncope necessitates ECG documentation before antiarrhythmic therapy
- Avoid vestibular suppressants in elderly due to fall risk and cognitive impairment
- Medication review is essential as polypharmacy commonly causes dizziness
- Anxiety-related dizziness responds to SSRIs, not chronic benzodiazepines
- Address metabolic causes (anemia, hypoglycemia) through specific replacement therapy
🔬 Pharmacology Study Tips:
- Understand mechanisms: Vestibular suppression, cardiovascular effects, metabolic corrections
- Know contraindications: Anticholinergics in glaucoma, benzodiazepines in elderly
- Remember monitoring requirements: Electrolytes (diuretics), supine BP (midodrine), ECG (antiarrhythmics)
- Recognize drug-induced dizziness: Antihypertensives, sedatives, anticholinergics